Supplementary Figures 1-11 and Supplementary Tables 1-2 from Blocking the CCL2–CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Fig. 1. Mice treated with CCL2 neutralizing antibody (nab) for 4 weeks did not show significant changes in body weight; Supplementary Fig. 2. CCR2 inhibitor therapy reduces chronic liver inflammation in miR-122 knockout (KO) mouse; Supplementary Fig. 3. CCL2 nab therapy did not reduce CD11bhighGr1+ inflammatory myeloid cells in the peripheral blood; Supplementary Fig. 4. Blocking the CCL2-CCR2 axis reduces hepatic macrophages; Supplementary Fig. 5. CCL2 nab does not alter the population of B cell, T cell, and NK cell in liver; Supplementary Fig. 6. CCR2 inhibitor therapy reduces CD11bhighGr1+ inflammatory cells in the KO mouse liver; Supplementary Fig. 7. 12-month-old male KO mice were assigned to vehicle and CCL2 nab treated groups based on serum AFP and body weight; Supplementary Fig. 8. CCL2 immunotherapy reduces tumoral p-STAT3, c-MYC, and p65 levels. Supplementary Fig. 9. CCL2 immunotherapy reduces the number of proliferative cells in the adjacent benign tumors; Supplementary Fig. 10. Blocking CCL2 by neutralizing antibody increases cell apoptosis; Supplementary Fig. 11 CCL2 nab therapy inhibits HCC development in KO mice by modulating tumor microenvironment; Supplementary Table 1. Primers used for RT-qPCR analysis; Supplementary Table 2. Serological analysis of 4 months old KO mice.
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362534569